

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/137424 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/5355 (2006.01)
C07D 413/14 (2006.01)

(21) International Application Number:

PCT/US2024/061246

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/613,537 21 December 2023 (21.12.2023) US

(71) Applicant: **BLACK DIAMOND THERAPEUTICS, INC.** [US/US]; One Main Street, 14th Floor, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **KUMAR, Santosh**; 537 Lowell Street, Lexington, Massachusetts 02420 (US). **MOSHOS, Kristos Adrian**; 9 Audubon Lane, Belmont, Massachusetts 02478 (US). **ZHANG, Wu-Yan**; 76 Wood Street, Lexington, Massachusetts 02421 (US). **FOROUGHI, Reza**; 609 Las Lomas, Pacific Palisades, California 90272 (US).

(74) Agent: **ERLACHER, Heidi** et al.; Cooley LLP, 1299 Pennsylvania Ave. NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: SOLID FORMS OF AN ERBB INHIBITOR



(57) Abstract: The present disclosure provides a morphic form of a pharmaceutically acceptable salt of Compound No. 1: (Compound No. 1) solvates thereof and hydrates thereof. The present disclosure also provides processes for preparing the morphic form and uses of the morphic form, e.g., in preventing or treating cancer.

WO 2025/137424 A1